psivida receives first rd payments from pfizer

ASX/Media RELEASE 20 February 2008
pSivida receives first R&D payments from Pfizer
Boston, MA and Perth, Australia (February 20, 2008) – pSivida Limited (NASDAQ:PSDV,
ASX:PSD, Xetra:PSI) today announced the receipt of US$500k as the first quarterly research and
development payment from Pfizer under the terms of the exclusive worldwide Collaborative
Research and License Agreement signed in April 2007 for pSivida’s controlled drug delivery
technologies in ophthalmic applications.
Over the last 10 months pSivida has received US$12m from Pfizer, including equity investments,
under the terms of that agreement and will receive up to an additional US$153.5m in development
and sales related milestones. Pfizer is the largest shareholder in Company holding approximately
10% of the outstanding shares.
“We are very pleased that the Pfizer licensing agreement is proceeding as expected,” said
pSivida’s Managing Director, Dr Paul Ashton.
-ENDSReleased
by:
pSivida Limited
Brian Leedman
Vice President, Investor Relations
pSivida Limited
Tel: + 61 (0) 412 281 780
[email protected]
US Public Relations
Beverly Jedynak
President
Martin E. Janis & Company, Inc
Tel: +1 (312) 943 1100 ext. 12
[email protected]
European Public Relations
Eva Reuter
Accent Marketing Limited
Tel: +49 (254) 393 0740
[email protected]
-2-